Advertisement
Screener

PMV PHARMACEUTICALS, INC. (PMVP) Material Contracts

PMV PHARMACEUTICALS, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-03-06: Form 10-K; Exhibit 10.19; Description Consulting Agreement, dated January 1, 2026, by and between the Registrant and Charles Baum, MD., Ph.D..
  • 2026-03-06: Form 10-K; Exhibit 10.11; Description Amended Outside Director Compensation Policy..
  • 2025-05-09: Form 10-Q; Exhibit 10.3; Description Amended and Restated Change in Control and Severance Policy Participation Agreement, dated November 5, 2025, by and between the Registrant and Robert Ticktin..
  • 2025-05-09: Form 10-Q; Exhibit 10.2; Description Offer Letter Agreement dated November 5, 2025, by and between the Registrant and Robert Ticktin..
FiledFormExhibitDescription
2026-03-0610-K10.19Consulting Agreement, dated January 1, 2026, by and between the Registrant and Charles Baum, MD., Ph.D.
2026-03-0610-K10.11Amended Outside Director Compensation Policy.
2025-05-0910-Q10.3Amended and Restated Change in Control and Severance Policy Participation Agreement, dated November 5, 2025, by and between the Registrant and Robert Ticktin.
2025-05-0910-Q10.2Offer Letter Agreement dated November 5, 2025, by and between the Registrant and Robert Ticktin.
2025-05-0910-Q10.1Amended Outside Director Compensation Policy.
2024-08-088-K10.1Lease Termination Agreement, dated August 5, 2024, by and between BMR-One Research Way LLC and PMV Pharmaceuticals, Inc.
2024-05-0910-Q10.42020 Employee Stock Purchase Plan and forms of agreements thereunder
2024-02-2910-K10.24Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 5, 2024, by and between the Registrant and Michael Carulli
2024-02-2910-K10.23Consulting Agreement, dated February 13, 2024, by and between the Registrant and Charles Baum, MD., Ph.D.
2024-02-2910-K10.23PDF COURTESY COPY
2024-02-2910-K10.22Amended and Restated Employment Letter, dated January 5, 2024, by and between the Registrant and Michael Carulli
2024-02-2910-K10.21Separation Agreement, dated January 5, 2024, by and between the Registrant and Leila Alland, M.D.
2024-02-2910-K10.20Consulting Agreement, dated January 5, 2024, by and between the Registrant and Winston Kung.
2024-02-2910-K10.15Amended Outside Director Compensation Policy.
2023-03-0110-K10.15Amended Outside Director Compensation Policy.
2022-08-0910-Q10.15Outside Director Compensation Policy., as amended on May 5, 2022
2022-05-1010-Q10.14Amended and Restated Change in Control and Severance Policy Participation Agreement, dated March 24, 2022, by and between the Registrant and Deepika Jalota, Pharm.D.
2022-03-0110-K10.17Consulting Agreement, dated May 21, 2021, by and between the Registrant and Richard Heyman, Ph.D., as amended on July 16, 2021
2022-03-0110-K10.14Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 14, 2022, by and between the Registrant and Deepika Jalota, Pharm.D.
2022-03-0110-K10.8Employment Offer Letter, dated February 22, 2021, by and between the Registrant and Deepika Jalota, Pharm.D.
2021-03-0310-K10.19Lease Agreement, dated January 8, 2021, by and between the Registrant and BMR-ONE RESEARCH WAY LLC.

Similar stocks

Stock NameCountryMarket CapPE Ratio
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39